Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | PREP | P48147 | 4/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12577662 | 0.82 | CA12 (0.44) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL2558325 | 0.81 | CA12 (0.34) | CA12CA1CA9PREPALOX5AP | |
| SCHEMBL7143162 | 0.80 | CA9 (0.45) | CA12CA1CA9PREPAPLNR | |
| SCHEMBL29953678 | 0.79 | TUBB4A (0.43) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL2022605 | 0.79 | CA12 (0.44) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL4977539 | 0.78 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL12492971 | 0.78 | CA12 (0.46) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL2114690 | 0.77 | CA12 (0.43) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL29951222 | 0.77 | CA12 (0.43) | CA12CA1CA9PREPHSP90AA1 | |
| SCHEMBL1620647 | 0.77 | CA12 (0.47) | CA12CA1CA9PREPHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981839-B1 | COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS | PROMEGA CORP (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2024-02-22 | — | — | US | disclosed |
| CN-112513188-B | Coelenterazine analogs | 普洛麦格公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11691976-B2 | Coelenterazine analogues | PROMEGA CORPORATION (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3841173-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112513188-A | Coelenterazine analogs | 普洛麦格公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020041579-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-02-27 | — | — | US | disclosed |
| EP-3191445-B1 | CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3191454-B1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-10-24 | — | — | EP | disclosed |
| US-10023519-B2 | Cyclobutane containing carboxylic acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-9938222-B2 | Cyclopropanecarboxylic acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170253554-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170247311-A1 | CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3191445-A1 | CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-3191454-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040223-A1 | CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040222-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062766-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | CA12 1061/4885CA1 2504/4885CA9 1806/4885 |
| US-11691976-B2 | Coelenterazine analogues | GLB1, SI, TCF7L2 | CA12 1061/4885CA1 2504/4885CA9 1806/4885 |
| US-20240059697-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | CA12 1061/4885CA1 2504/4885CA9 1806/4885 |
| US-10023519-B2 | Cyclobutane containing carboxylic acid GPR120 modulators | GPR68, GPR88, GPR55 | CA12 1732/4885CA1 2539/4885CA9 2755/4885 |
| US-20170253554-A1 | CYCLOPROPANECARBOXYLIC ACID GPR120 MODULATORS | GPR88, GPBAR1, GPR68 | CA12 2098/4885CA1 2808/4885CA9 3107/4885 |
| US-20170247311-A1 | CYCLOBUTANE CONTAINING CARBOXYLIC ACID GPR120 MODULATORS | GPR68, GPR88, GPR55 | CA12 1732/4885CA1 2539/4885CA9 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.